Addyi (Flibanserin) Safety Profile in Hispanic and Latino Patients

How Flibanserin Works and Why Ethnicity Matters

Flibanserin acts on serotonin receptors in the brain, functioning as an agonist at 5-HT1A and an antagonist at 5-HT2A receptors. This dual mechanism modulates the balance between excitatory and inhibitory neurotransmitters involved in sexual desire. The drug is metabolized primarily through CYP3A4, with secondary contributions from CYP2C19 1.

Pharmacogenomic Variation Across Populations

Ethnic differences in drug-metabolizing enzyme activity can shift plasma concentrations of any hepatically cleared medication. CYP2C19 polymorphisms vary substantially across racial and ethnic groups. According to data from the Clinical Pharmacogenetics Implementation Consortium (CPIC), approximately 2-5% of Hispanic and Latino individuals carry CYP2C19 poor-metabolizer alleles, compared to roughly 2-3% of European-descent populations 2. That difference is modest. But it compounds when layered on top of metabolic factors more prevalent in Hispanic and Latino communities.

Why the Metabolic Context Adds Risk

The CDC reports that U.S. Hispanic and Latino adults have a type 2 diabetes prevalence of approximately 17.4%, compared to 11.2% among non-Hispanic white adults 3. Insulin resistance and metabolic syndrome frequently accompany this burden. Flibanserin's label warns against use with hepatic impairment, and nonalcoholic fatty liver disease (now termed MASLD) occurs at elevated rates in Hispanic populations due in part to the PNPLA3 I148M variant 4. Hepatic dysfunction of any degree can slow CYP3A4-mediated clearance, raising drug exposure and the probability of adverse events.

Clinical Trial Evidence: What the Subgroup Data Show

The BEGONIA trial (N=1,087) was the largest Phase III study establishing flibanserin 100 mg nightly as effective for premenopausal hypoactive sexual desire disorder (HSDD). The trial showed that flibanserin produced a statistically significant increase in satisfying sexual events (SSEs) and a reduction in distress compared to placebo over 24 weeks 1.

Hispanic/Latino Enrollment Numbers

Like many key trials in sexual medicine, BEGONIA enrolled a predominantly white cohort. Hispanic and Latino participants represented a small fraction of the total sample. This underrepresentation limits the statistical power of ethnicity-stratified subgroup analyses. The FDA's 2015 approval review noted that across all flibanserin trials (BEGONIA, DAISY, VIOLET, and SNOWDROP), ethnic minority subgroups were too small for standalone efficacy or safety conclusions 5.

Pooled Safety Data

The FDA medical review for flibanserin's approval reported that the most common adverse events across all trials were dizziness (11.4% vs. 2.2% placebo), somnolence (11.2% vs. 3.1%), nausea (10.4% vs. 3.9%), and fatigue (9.2% vs. 5.7%) 5. While no ethnicity-specific signal emerged from pooled data, the review acknowledged the enrollment limitations. Dr. Julia Johnson, then-chair of the FDA's Bone, Reproductive and Urologic Drugs Advisory Committee, stated during the 2015 hearing: "We simply do not have enough data in minority subgroups to draw firm safety conclusions, and post-marketing surveillance should address this gap."

Post-Marketing Surveillance Findings

The REMS program mandated at approval requires prescriber certification and patient counseling about the alcohol interaction. Post-marketing reports submitted to the FDA Adverse Event Reporting System (FAERS) have not identified a disproportionate safety signal in Hispanic or Latino women specifically 6. Sprout Pharmaceuticals has not published ethnicity-stratified post-marketing safety analyses as of 2026.

CYP Enzyme Pharmacogenomics and Dosing Implications

The pharmacokinetic profile of flibanserin depends heavily on CYP3A4 activity. Co-administration with moderate or strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, certain HIV protease inhibitors) is contraindicated because it can increase flibanserin area under the curve (AUC) by 2- to 4.5-fold 7.

CYP2C19 Polymorphism Frequencies

PharmGKB data on CYP2C19 allele frequencies show that the *2 loss-of-function allele occurs in roughly 10-15% of Hispanic/Latino individuals (allele frequency), with the *17 gain-of-function allele at approximately 15-20% 8. Because CYP2C19 is a secondary pathway for flibanserin metabolism, poor-metabolizer status alone is unlikely to produce clinically dangerous exposure increases. The risk compounds when CYP2C19 poor-metabolizer status coincides with partial CYP3A4 inhibition from a concomitant medication or grapefruit juice intake.

Practical Pharmacogenomic Screening

The Endocrine Society and CPIC do not currently recommend routine CYP testing before prescribing flibanserin. The drug's label does not require it. Pre-prescription pharmacogenomic testing may still have value in Hispanic and Latino patients who take CYP3A4-interacting medications for diabetes management (such as certain oral antifungals for recurrent candidiasis in diabetic patients). A 2021 review in Clinical Pharmacology & Therapeutics noted that "population-level pharmacogenomic data remain insufficient to guide flibanserin dose adjustments by ethnicity, but individual genotyping can reduce adverse event risk in patients with polypharmacy" 9.

Metabolic Comorbidities and Safety Overlap

Hispanic and Latino women prescribed flibanserin are more likely than non-Hispanic white women to carry concurrent diagnoses of obesity, insulin resistance, and MASLD. Each of these conditions can alter hepatic drug metabolism.

Obesity and Volume of Distribution

Flibanserin is lipophilic. In patients with a BMI above 30, the volume of distribution increases, which can alter both peak plasma concentration and elimination half-life. The FDA approval package did not include body-weight-stratified pharmacokinetic analyses 5. Given that approximately 42.5% of Hispanic women in the U.S. Have obesity compared to 39.8% of non-Hispanic white women (NHANES 2017-2020 data) 10, this pharmacokinetic knowledge gap affects a large segment of potential patients.

MASLD and Hepatic Clearance

The prevalence of MASLD reaches 45-50% in U.S. Hispanic populations, driven partly by the PNPLA3 I148M polymorphism, which is carried by approximately 49% of Hispanic individuals versus 23% of European-descent individuals 4. Flibanserin is contraindicated in hepatic impairment. Mild steatosis without fibrosis does not technically meet the label's definition of hepatic impairment, but subclinical reductions in CYP3A4 activity have been documented in patients with steatohepatitis 11.

Diabetes-Related Medication Interactions

Metformin, the first-line diabetes medication, does not interact with CYP enzymes and poses no pharmacokinetic risk with flibanserin. SGLT2 inhibitors (empagliflozin, dapagliflozin) and DPP-4 inhibitors (sitagliptin) are also CYP-neutral. Risk arises when patients take azole antifungals for diabetes-associated vulvovaginal candidiasis. Fluconazole is a moderate CYP3A4 inhibitor and is contraindicated with flibanserin 7. The prescribing clinician should review the full medication list and screen for antifungal use before starting Addyi.

The Alcohol Interaction: Context-Specific Risks

Flibanserin carries an FDA boxed warning for the alcohol interaction. In a dedicated interaction study, concomitant administration of flibanserin 100 mg with 0.6 g/kg ethanol caused severe hypotension and syncope requiring medical intervention in some subjects 5.

ALDH2 and ADH1B Variants

Unlike East Asian populations, Hispanic and Latino individuals do not carry the ALDH22 variant at appreciable frequencies. The ADH1B2 allele, which accelerates ethanol oxidation, is found in roughly 10-15% of some Hispanic subgroups. This means alcohol metabolism is generally comparable to European-descent populations in most Hispanic and Latino patients. The boxed warning applies equally. No dose modification based on ancestry is recommended.

Clinical Counseling Points

The REMS requirement mandates that every patient receiving flibanserin, regardless of ethnicity, be counseled on the alcohol interaction. Prescribers should verify alcohol use patterns at each visit. The bedtime dosing schedule was designed specifically to minimize the window of hypotension risk during waking hours.

Practical Prescribing Recommendations

For clinicians treating Hispanic and Latino women with HSDD, flibanserin remains a therapeutic option when nonpharmacologic approaches have been insufficient. Several targeted steps can reduce risk.

Pre-Prescription Checklist

Screen for hepatic steatosis or fibrosis. A FIB-4 score or transient elastography can help identify patients with subclinical liver disease who may clear flibanserin more slowly 12. Review the medication list for CYP3A4 inhibitors, paying specific attention to antifungal prescriptions. Document alcohol use with a validated screening tool (AUDIT-C).

Monitoring After Initiation

Measure blood pressure at baseline and within four weeks of starting therapy. Patients should report any episodes of dizziness, presyncope, or somnolence that impair driving or daily function. If a patient also carries a diagnosis of metabolic syndrome, consider checking liver enzymes at baseline and at three months.

When to Consider Pharmacogenomic Testing

Genotyping for CYP2C19 is reasonable when a patient is on multiple interacting medications and the clinical picture suggests slower-than-expected drug clearance. The cost of CYP2C19 testing has fallen below $200 at most commercial labs, and some insurers now cover it as part of pharmacogenomic panels 8.

Gaps in the Evidence

The single largest barrier to precise safety guidance for Hispanic and Latino patients taking flibanserin is inadequate representation in clinical trials. Across all four Phase III trials, Hispanic enrollment ranged from approximately 8-15% of participants, well below the U.S. Census proportion of over 19% 5.

What Needs to Happen

The FDA's 2024 Diversity Action Plan guidance now requires sponsors of new drug applications to submit enrollment goals for racial and ethnic subgroups 13. This would apply to any future flibanserin indication expansion or reformulation. Post-marketing studies specifically powered for Hispanic and Latino safety outcomes have not been mandated but have been recommended by multiple advisory panels.

The PharmGKB Knowledge Gap

PharmGKB lists flibanserin as having limited pharmacogenomic annotation. No Clinical Annotation exists linking CYP2C19 genotype to flibanserin dosing adjustments 8. Until population-specific pharmacokinetic studies are conducted, prescribers must rely on general CYP interaction principles and individual patient assessment rather than ancestry-based dose modifications.

Flibanserin 100 mg nightly remains the only FDA-approved dose, with no ethnicity-based adjustment recommended. Clinicians should monitor Hispanic and Latino patients for hypotension and somnolence with the same vigilance applied to any patient, while giving additional attention to hepatic health screening and CYP3A4 inhibitor co-prescriptions that are statistically more prevalent in this population.